Inner ear drug delivery system from the clinical point of view.

Acta oto-laryngologica. Supplementum Pub Date : 2010-11-01 DOI:10.3109/00016489.2010.486801

Tatsunori Sakamoto, Takayuki Nakagawa, Rie T Horie, Harukazu Hiraumi, Norio Yamamoto, Yayoi S Kikkawa, Juichi Ito

{"title":"Inner ear drug delivery system from the clinical point of view.","authors":"Tatsunori Sakamoto, Takayuki Nakagawa, Rie T Horie, Harukazu Hiraumi, Norio Yamamoto, Yayoi S Kikkawa, Juichi Ito","doi":"10.3109/00016489.2010.486801","DOIUrl":null,"url":null,"abstract":"Conclusion: Three types of inner ear drug delivery systems (DDS) that were ready to be applied in clinics were developed.Objectives: To develop clinically applicable inner ear DDS for the treatment of inner ear disorders.Methods: Inner ear DDS using clinically applicable materials were developed and evaluated.Results: The systemic application of stealth-type nanoparticles encapsulating betamethasone provided superior therapeutic results for the treatment of noise-induced hearing loss compared with the systemic application of betamethasone in mice. Microparticles made of biodegradable polymer (poly (lactic/glycolic) acid, PLGA) encapsulating lidocaine were placed on the round window membrane of guinea pigs, and resulted in reasonable concentrations of lidocaine in the cochlea without serious adverse effects. The phase I/IIa clinical trial of the application of insulin-like growth factor-1 (IGF-1) in combination with gelatin hydrogel on the round window membrane was conducted, recruiting patients with acute sensorineural hearing loss after the failure of systemic application of steroids.","PeriodicalId":7027,"journal":{"name":"Acta oto-laryngologica. Supplementum","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00016489.2010.486801","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta oto-laryngologica. Supplementum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/00016489.2010.486801","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 14

Abstract

Conclusion: Three types of inner ear drug delivery systems (DDS) that were ready to be applied in clinics were developed.

Objectives: To develop clinically applicable inner ear DDS for the treatment of inner ear disorders.

Methods: Inner ear DDS using clinically applicable materials were developed and evaluated.

Results: The systemic application of stealth-type nanoparticles encapsulating betamethasone provided superior therapeutic results for the treatment of noise-induced hearing loss compared with the systemic application of betamethasone in mice. Microparticles made of biodegradable polymer (poly (lactic/glycolic) acid, PLGA) encapsulating lidocaine were placed on the round window membrane of guinea pigs, and resulted in reasonable concentrations of lidocaine in the cochlea without serious adverse effects. The phase I/IIa clinical trial of the application of insulin-like growth factor-1 (IGF-1) in combination with gelatin hydrogel on the round window membrane was conducted, recruiting patients with acute sensorineural hearing loss after the failure of systemic application of steroids.

查看原文本刊更多论文

从临床角度探讨内耳给药系统。

结论:研制出3种适合临床应用的内耳给药系统(DDS)。目的:开发临床适用的内耳DDS治疗内耳疾病。方法:采用临床适用材料研制内耳DDS并进行评价。结果:与全身应用倍他米松相比，全身应用隐身型纳米颗粒包埋倍他米松对小鼠噪声性听力损失的治疗效果更好。将可生物降解聚合物(聚乳酸/乙醇酸，PLGA)包封利多卡因制成微粒置于豚鼠圆窗膜上，使耳蜗内利多卡因浓度合理，且无严重不良反应。开展了胰岛素样生长因子-1 (IGF-1)联合明胶水凝胶在圆窗膜上应用的I/IIa期临床试验，招募了系统性应用类固醇失败后急性感音神经性听力损失患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta oto-laryngologica. Supplementum

自引率

0.00%

发文量